Nasopharyngeal carcinoma in children and young adults—Beyond 5-year survival

Tal Ben-Ami*, Shifra Ash, Miri Ben-Harosh, Herzel Gavriel, Michael Weintraub, Shoshana Revel-Vilk, Myriam Ben-Arush

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Nasopharyngeal carcinoma (NPC) is a rare and locally aggressive form of childhood cancer. Treatment of NPC includes chemotherapy and radiotherapy. With current treatment protocols, survival rates for patients with nonmetastatic disease is over 80%. Data regarding very late events including long-term treatment-related morbidities and second malignancies are scarce. We present our data on 42 patients with NPC treated in Israel between 1989 and 2014, and followed until 2019. During follow up, five patients had disease recurrence, and four children developed secondary malignancy. Median time to diagnosis of secondary malignancy was 105 months. Eighty-eight percent of patients have long-term treatment-related morbidities.

Original languageEnglish
Article numbere28494
JournalPediatric Blood and Cancer
Issue number9
StatePublished - 1 Sep 2020
Externally publishedYes


  • late toxicities
  • long-term follow up
  • nasopharyngeal carcinoma
  • second malignancies


Dive into the research topics of 'Nasopharyngeal carcinoma in children and young adults—Beyond 5-year survival'. Together they form a unique fingerprint.

Cite this